Are orphan drug companies the pick of the pharmaceutical industry?

Nature Reviews Drug Discovery

Volumn 13, Issue 1, 2014, Pages 10-

  Morel, Thomas ^a,b   Popa, Cedric ^c   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Deloitte Financial Advisory Services (FAS)   (Belgium)

^c Deloitte FAS ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; INVESTMENT; NOTE; PRIORITY JOURNAL; PROFIT; DRUG MANUFACTURE; ECONOMICS; HUMAN; TRENDS;

DRUG COSTS; HUMANS; INVESTMENTS; ORPHAN DRUG PRODUCTION;

EID: 84891703259     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4205     Document Type: Note

References (0)